Rob Bresnahan, Representative
sell disclosed on 8 May 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Public company research profile
This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.
Company research history
Moderna, Inc. - Common Stock (MRNA)
Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.
10 disclosures
4 insiders
0 cluster signals
-1.9% avg. 30d outcome
Company facts
- Ticker / ISIN
- MRNA / Not available
- Exchange
- Not available
- Country
- US
- Sector
- Not available
Disclosure history
Rob Bresnahan, Representative
buy disclosed on 27 Mar 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Julie Johnson, Representative
sell disclosed on 12 Feb 2025 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Josh Gottheimer, Representative
sell disclosed on 7 Mar 2024 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- +5.6%
Josh Gottheimer, Representative
sell disclosed on 15 Oct 2023 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Daniel Goldman, Representative
sell disclosed on 13 Aug 2023 via House STOCK Act disclosures
- Transaction value
- US$50,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%
Daniel Goldman, Representative
buy disclosed on 19 May 2023 via House STOCK Act disclosures
- Transaction value
- US$50,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -1.6%
Josh Gottheimer, Representative
buy disclosed on 20 Apr 2023 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -10.2%
Daniel Goldman, Representative
sell disclosed on 17 Apr 2023 via House STOCK Act disclosures
- Transaction value
- US$50,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -12.8%
Josh Gottheimer, Representative
sell disclosed on 17 Apr 2022 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- 0.0%